Revelation Biosciences, Inc. (REVB) Stock Price & Analysis
Revelation Biosciences, Inc. (REVB) fell 0.93% to USD 1.06 as of July 25, 2026 at 03:53 UTC, according to Nexqual real-time market data.
REVB last closed at USD 1.07; the session ranged USD 1.04–1.08 on volume of 31,557 shares. Market capitalization is $4.14M, with a 52-week range of USD 0.88–11.96 (NCM). Source: Nexqual, July 25, 2026 at 03:53 UTC.
Key Statistics (as of July 25, 2026 at 03:53 UTC)
| Price | USD 1.06 |
|---|---|
| Change | ▼ 0.93% (down) |
| Previous Close | USD 1.07 |
| Open | USD 1.05 |
| Day Range | USD 1.04 – 1.08 |
| 52-Week Range | USD 0.88 – 11.96 |
| Volume | 31,557 shares |
| Market Cap | $4.14M |
| Exchange | NCM |
Technical Analysis (REVB)
Nexqual's technical model rates REVB "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:53 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.6 (neutral) |
| vs SMA50 | Above (USD 1.05) |
| MACD | 0.02 (positive) |
Analyst Ratings (REVB)
Wall Street analysts rate REVB "None" based on 2 analysts, with a mean price target of USD 19.25 (range USD 16–22.5), per Nexqual as of July 25, 2026 at 03:53 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 19.25 |
| High Target | USD 22.5 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (REVB)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD -0.83 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.71 vs est -1.15 ▼ miss |
| 2025-12-31 | USD -1.65 vs est -3.66 ▲ beat |
| 2025-09-30 | USD -7.08 vs est -5.34 ▼ miss |
| 2025-06-30 | USD -28.04 vs est -24.6 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:53 UTC.
Financials & Fundamentals (REVB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -124.41% |
| Debt / Equity | 5.84 |
| Current Ratio | 10.02 |
| Total Cash | $14.11M |
| Total Debt | $759,044 |
| Free Cash Flow | $-5.16M |
Source: Nexqual, July 25, 2026 at 03:53 UTC.
Financial Health Score (REVB)
Nexqual rates Revelation Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -124%, ROA -66.2% |
Ownership (REVB)
| Insider Ownership | +4.79% |
|---|---|
| Institutional Ownership | +12.79% |
| Shares Outstanding | 3.91M |
| Float | 3.44M |
| Short % of Float | +0.37% |
Source: Nexqual, July 25, 2026 at 03:53 UTC.
Leadership (REVB)
Revelation Biosciences, Inc. is led by James M. Rolke (age 56), Chairman & CEO, per Nexqual as of July 25, 2026 at 03:53 UTC.
| Chairman & CEO | James M. Rolke (age 56) |
|---|---|
| CFO & Corporate Secretary | Chester Stanley Zygmont (age 45) |
| Vice President of Human Resources & Investor Relations | Sandra Vedrick |
| Senior Director of Clinical Projects | Carol Odle |
Major Backers & Investors (REVB)
Notable institutional backers of Revelation Biosciences, Inc. include Armistice Capital, LLC, Sabby Management, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 03:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 8.27% |
| Sabby Management, LLC | 2.54% |
| Fidelity | 1.08% |
| Xtx Topco Ltd | 0.29% |
| UBS Group AG | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.11% |
| Vanguard Group | 0.34% |
Source: Nexqual, July 25, 2026 at 03:53 UTC.
From Revelation Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms, and Product Candidates.   18   As of February 23, 2026, our patent portfolio includes one patent family directed to MPLA formulations, including Gemini.
- Potential Future Applications for Gemini The Gemini Platform Our current therapeutic programs are based on our proprietary Gemini formulation of PHAD ® , a synthetic version of monophosphoryl lipid A ("MPLA") with a well-established biology.
- The CDC says Medicare in 2015 alone had an annual expenditure of over $10 billion and growing for AKI, with spending for AKI related costs of approximately $42,077 per patient.
- For Product Candidates regulated under the FD&C Act, FDA must approve a New Drug Application ("NDA").
Partnerships
- Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis for submission of a new drug application (NDA).
- P-values generated using two-tailed t-test with alpha at 5%.   16   Development Plans AKI Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study comprising approximately 300 patients with AKI and a primary composite endpoint of death and/or need for dialysis, the data from which can be used for submission of a new drug application (NDA).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| VRAX | Virax Biolabs Group Limited | USD 3.19 | ▼ 12.36% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▲ 0.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:53 UTC. This page is informational and not investment advice.